Wall Street Zen Upgrades Urogen Pharma (NASDAQ:URGN) to Hold

Urogen Pharma (NASDAQ:URGN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other brokerages have also recently commented on URGN. Piper Sandler began coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target for the company. HC Wainwright cut their price target on shares of Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Guggenheim reaffirmed a “buy” rating and set a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Scotiabank reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the company a “neutral” rating in a report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.00.

Urogen Pharma Price Performance

Shares of URGN stock opened at $18.79 on Friday. The stock has a market cap of $869.23 million, a P/E ratio of -5.66 and a beta of 1.10. The company has a fifty day moving average price of $18.19 and a two-hundred day moving average price of $12.90. Urogen Pharma has a one year low of $3.42 and a one year high of $21.71.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, equities research analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the sale, the general counsel directly owned 41,492 shares in the company, valued at approximately $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the sale, the insider owned 148,229 shares in the company, valued at approximately $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,062 shares of company stock worth $465,115. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its stake in Urogen Pharma by 9.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after buying an additional 797 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Urogen Pharma by 4.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock worth $231,000 after buying an additional 969 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Urogen Pharma by 0.8% during the 1st quarter. Wellington Management Group LLP now owns 148,078 shares of the company’s stock worth $1,638,000 after buying an additional 1,125 shares in the last quarter. Main Street Financial Solutions LLC boosted its holdings in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after buying an additional 1,968 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Urogen Pharma by 4.3% during the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company’s stock worth $591,000 after buying an additional 2,196 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.